Step therapy is an insurance requirement that forces you to try one or more cheaper medications before your plan will cover Mounjaro. In practice, this means your insurer won’t approve Mounjaro as a first option for type 2 diabetes, even if your doctor prescribes it. You’ll need to use specific lower-cost drugs first, show they didn’t work well enough, and only then will coverage for Mounjaro kick in. The process can take months.
How Step Therapy Works
Insurance companies organize medications into “steps.” Step 1 drugs are the ones they want you to try first, usually because they’re older, cheaper, or available as generics. Step 2 drugs, like Mounjaro, are only covered after you’ve gone through Step 1. The logic from the insurer’s perspective is cost control: why pay for an expensive newer drug if an older one works?
For Mounjaro specifically, the first step almost always includes metformin, the most widely prescribed type 2 diabetes medication. Beyond metformin, many plans also require you to try at least one older injectable in the same drug class. Blue Cross Blue Shield of Massachusetts, for example, places drugs like Trulicity and Byetta in Step 1 and requires evidence of a paid claim or documented use of two Step 1 drugs before approving Mounjaro. MassHealth goes further, requiring an inadequate response to metformin combined with a drug like Trulicity, liraglutide (generic Victoza), or Byetta, plus an inadequate response or contraindication to Ozempic.
The specifics vary by insurer and even by plan within the same insurer, so your step therapy path may look different from someone else’s.
What Counts as “Failing” a Step 1 Drug
Insurers don’t just want you to try a medication briefly. They define “inadequate response” with specific timeframes and clinical thresholds. MassHealth, for instance, defines it as at least 90 days of therapy within a 120-day window. That means roughly three months on each required medication before you can move on.
Aetna’s criteria illustrate the clinical bar you need to clear. To qualify for Mounjaro, you typically need to show one of the following: an inadequate treatment response to metformin, an intolerance or side effects that prevent you from continuing metformin, a medical contraindication to metformin, or a need for combination therapy with an A1C of 7.5% or greater. If you’re already on Mounjaro and have been stable for at least three months, some plans will continue coverage as long as your A1C has dropped since starting.
“Failing” a drug can mean your blood sugar stayed too high despite taking it as prescribed, or it can mean you experienced side effects serious enough that your doctor stopped it. Both paths satisfy the requirement, but you’ll need documentation either way.
Why the Process Takes So Long
The math adds up quickly. If your insurer requires you to try metformin for 90 days and then an older injectable for another 90 days, that’s six months of waiting before you’re even eligible for Mounjaro. Some plans require trials of two or three Step 1 drugs, which can stretch the timeline to nine months or more. During this period, your diabetes management may not be optimal, which is one of the main criticisms of step therapy policies.
Each transition between steps also involves paperwork. Your doctor submits documentation showing the Step 1 drug didn’t work, the insurer reviews it, and then either approves or denies the next step. Delays in any part of that chain extend the wait.
How to Get an Exception
You’re not always locked into the step therapy sequence. Most insurers allow exceptions if your doctor can demonstrate medical necessity. The most common reasons that qualify:
- Contraindication to a Step 1 drug. If you have a medical reason you can’t safely take metformin (such as severe kidney disease), you can skip that step. Similarly, if you have a documented adverse reaction to required injectable medications like Trulicity or Byetta, that counts.
- Prior use of Step 1 drugs. If you already tried and failed a required medication before your current insurance plan, your doctor can submit records from that earlier treatment. You shouldn’t have to repeat a trial you’ve already done.
- Clinical urgency. If your A1C is dangerously high and your doctor believes waiting months on less effective drugs poses a real health risk, they can argue for an exception.
For any of these, your doctor will need to submit a prior authorization request with supporting documentation: lab results, prescription history, notes on side effects, and a clinical rationale for why Mounjaro is necessary now rather than after completing the required steps.
What to Do if You’re Denied
A denial isn’t the end of the road. You have the right to appeal, and appeals do succeed. The key is thorough documentation. Your doctor’s appeal should include your full prescription history showing which Step 1 drugs you tried, lab results (especially A1C values) showing those drugs didn’t adequately control your blood sugar, records of any adverse reactions or intolerances, and a clear explanation of why Mounjaro is the appropriate next treatment.
Timing matters for the documentation. If your insurer defines an adequate trial as 90 days within a 120-day period, make sure your pharmacy records reflect that you actually filled and used the medication for that full window. Gaps in refills can give the insurer grounds to say you didn’t complete the required trial.
Many states have also passed step therapy reform laws that give you additional protections, such as the right to an expedited exception review or limits on how many drugs an insurer can require you to fail first. Check your state’s insurance regulations or ask your doctor’s office if any state-level protections apply to your situation.
Step Therapy for Weight Loss vs. Diabetes
Mounjaro is FDA-approved for type 2 diabetes. Its sister drug Zepbound uses the same active ingredient but is approved for weight management. Step therapy requirements for diabetes coverage are well established, as described above. Weight loss coverage is a different landscape entirely: many insurance plans don’t cover weight management medications at all, and those that do often have their own separate step therapy requirements, which may include trying older weight loss drugs first.
If you’re seeking Mounjaro specifically for type 2 diabetes, the step therapy path revolves around metformin and older injectables. If your goal is weight loss, the coverage picture is more complicated and depends heavily on whether your plan covers anti-obesity medications in the first place.